NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Harbinger Health

Harbinger Health

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://harbinger-health.com/

Last Round

Series B

Extension

Apr 14, 2026

Total Funding Raised

$290M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Harbinger Health is a biotechnology company that develops AI-enabled, blood-based multi-cancer detection tests designed to identify cancer at its earliest stages.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

multi-cancer detectionMCEDliquid biopsycfDNA methylationearly cancer detectioncancer screeningdiagnostic platformoncology diagnosticsblood-based testclinical diagnosticsbiotech startupprecision oncologycancer biomarkerclinical validation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Harbinger Health Comps

Public and private peers based on sector, stage, and business model.

Harbinger Health comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Harbinger Health Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionApr 14, 2026
Series BSep 28, 2023
Series ADec 7, 2021

Key People

Founding team and executive leadership

MPharm Gisela Paulsen

Chief Operating Officer

Executive Team

Harbinger Health Investors

Notable investors and investment history

Harbinger Health investors
InvestorRounds
Pictet GroupSeries B Extension, Series B
M&G InvestmentsSeries B Extension, Series B
Partners InvestmentSeries B Extension, Series B
Flagship PioneeringSeries B Extension, Series A, Series B
M&G plcSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Models infer lung cancer progression from blood draw cfDNA methylation data.

  • Apr 14, 2026

    $100M round raised.

Harbinger Health Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Harbinger Health Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Harbinger Health's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range65
Year Founded2020
Last FundingApr 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.